PAREXEL EXPERTS TO PRESENT ADVANTAGES OF HARNESSING THE POWER OF CONVERGENCE AT DIA 2011 Thought leaders to address efficiencies realized through combined technology solutions and clinical processes, innovative development approaches, strategic partnering
Boston, MA, June 7, 2011—In alignment with the theme “Convergence of Science, Medicine, and Health” of the Drug Information Association (DIA) 47th Annual Meeting, being held June 19-23, 2011 in Chicago, experts from PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, will address key advantages in harnessing the power of convergence.
During the meeting, thought leaders from PAREXEL will address how the biopharmaceutical industry can significantly increase efficiency by embracing new operating models based on a convergence of technology solutions and clinical processes, as well as innovative development approaches and strategic partnering best practices. PAREXEL experts will also provide insights into innovative trial design approaches and optimal regulatory, clinical, and commercialization pathways for drug development in emerging biopharmaceutical markets.
These topics will be discussed during executive briefings held at the PAREXEL Booth 1623 in the exhibit hall, as well as through nearly 20 presentations to be delivered by PAREXEL experts at the meeting. Highlights of DIA program sessions, being chaired or presented by PAREXEL experts, include:
Monday, June 20
- 10:30 a.m.: (Track 7 A—IT Methods and Technologies) “Blurring the Boundaries Between Technologies: Examples of Next Generation Clinical Trial Technology Integration,” Chair: Bill Byrom, Ph.D., Senior Director Product Strategy
- 10:30 a.m.: (Track 4—Nonclinical and Early Clinical Translational Development) “The Role of Biomarkers in the Rapid Development of New Medicines: A Scientific and Regulatory Perspective,” Chair: Cecil Nick, B.Sc. (Hons), Vice President, Technical Consulting
- 1:30 p.m.: (Track 9 C—Regulatory Affairs and Science, Quality, and GxP Compliance) “Japan Registration and Global Drug Development,” Chair: Alberto Grignolo, Ph.D., Corporate Vice President, Global Strategy and Services
Tuesday, June 21
- 10:00 a.m.: (Track 3—Outsourcing Strategies and Innovative Partnering Models) “Committing to Two Partners: A Look at a Strategic CRO Sourcing Initiative,” Joshua Schultz, Corporate Vice President, Strategic Account Leadership
- 10:00 a.m.: (Track 10 B—Public Policy/Health Care Compliance) “Pharmaceutical Pricing and Reimbursement Policies and Practices in Asia Pacific and Latin America: Impact on Drug Development,” Chair: Alberto Grignolo, Ph.D., Corporate Vice President, Global Strategy and Services
- 1:30 p.m.: (Track 2—Development Planning) “Global Pharmaceutical Development in Emerging Markets,” Diego Glancszpigel, Vice President, Latin America
# # #
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 10,350 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated restructuring charge of approximately $15 million over the fourth quarter of Fiscal Year 2011 as well as the first and second quarters of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 as filed with the SEC on May 10, 2011, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.